Monthly Archives: May 2022

Genprex to Present at Upcoming Investor Conference in May 2022

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More

Genprex’s Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors

Read More

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

Company achieves major milestones in clinical development programs in 2022

Patient treatment in Acclaim-2 clinical trial commences

Read More